Primary treatment, response to primary treatment, and recurrence and progression*
| Treatment | Overall cohort (n=453) | Early-stage disease (n=133) | Locally advanced disease (n=226) | Advanced disease (n=94) | P value |
| SX+CH+RT | 124 (27.4) | 52 (39.1) | 67 (29.6) | 5 (5.3) | <0.0001 |
| SX+CH | 66 (14.6) | 41 (30.8) | 14 (6.2) | 11 (11.7) | |
| SX+RT | 36 (7.9) | 13 (9.8) | 23 (10.2) | 0 (0.0) | |
| CH+RT | 97 (21.4) | 13 (9.8) | 71 (31.4) | 13 (13.8) | |
| SX | 19 (4.2) | 13 (9.8) | 6 (2.7) | 0 (0.0) | |
| RT | 44 (9.7) | 1 (0.8) | 40 (17.7) | 3 (3.2) | |
| CH | 59 (13.0) | 0 (0.0) | 4 (1.8) | 55 (58.5) | |
| No treatment | 8 (1.8) | 0 (0.0) | 1 (0.4) | 7 (7.4) | |
| Primary chemotherapy agents | |||||
| Cisplatin/carboplatin+etoposide | 303 (87.6) | 96 (90.6) | 137 (87.8) | 70 (83.3) | 0.2115 |
| Cisplatin/carboplatin+other | 33 (9.5) | 6 (5.7) | 15 (9.6) | 12 (14.3) | |
| None | 2 (0.6) | 0 (0.0) | 2 (1.3) | 0 (0.0) | |
| Other | 6 (1.7) | 2 (1.9) | 2 (1.3) | 2 (2.4) | |
| Cisplatin/carboplatin alone | 2 (0.6) | 2 (1.9) | 0 (0.0) | 0 (0.0) | |
| Concurrent chemotherapy | |||||
| Yes | 253 (84.1) | 65 (82.3) | 172 (85.6) | 16 (76.2) | 0.4288 |
| No | 48 (15.9) | 14 (17.7) | 29 (14.4) | 5 (23.8) | |
| Concurrent chemotherapy agents | |||||
| C/C+E | 122 (48.2) | 32 (49.2) | 85 (49.4) | 5 (31.3) | 0.0749 |
| C/C alone | 116 (45.8) | 32 (49.2) | 75 (43.6) | 9 (56.3) | |
| C/C+other | 7 (2.8) | 1 (1.5) | 4 (2.3) | 2 (12.5) | |
| Other | 8 (3.2) | 0 (0.0) | 8 (4.7) | 0 (0.0) | |
| Brachytherapy | |||||
| Yes | 237 (52.3) | 57 (42.9) | 158 (69.9) | 22 (23.4) | 0.0125 |
| No | 90 (19.9) | 23 (17.3) | 48 (21.2) | 19 (20.2) | |
| Not reported | 126 (27.8) | 53 (39.8) | 20 (8.8) | 53 (56.4) | |
| Cycles of C/C+E, median (range) | 5 (2–12) | 4 (2–7) | 4 (2–9) | 6 (2–12) | 0.007 |
| Cycles of C/C+E chemotherapy | |||||
| <5 | 131 (44.1) | 49 (52.7) | 59 (44.0) | 23 (32.9) | 0.0423 |
| ≥5 | 166 (55.9) | 44 (47.3) | 75 (56.0) | 47 (67.1) | |
| Response to primary treatment | |||||
| Complete response | 280 (61.8) | 115 (86.5) | 147 (65.0) | 18 (19.1) | <0.0001 |
| Partial response | 27 (6.0) | 0 (0.0) | 12 (5.3) | 15 (16.0) | |
| Mixed response | 15 (3.3) | 2 (1.5) | 4 (1.8) | 9 (9.6) | |
| Stable disease | 4 (0.9) | 0 (0.0) | 1 (0.4) | 3 (3.2) | |
| Progressive or new disease | 118 (26.0) | 16 (12.0) | 56 (24.8) | 46 (48.9) | |
| Not reported | 9 (2.0) | 0 (0.0) | 6 (2.7) | 3 (3.2) | |
| Follow-up time, median (range), months | 26.7 (22.4–30.4) | 52.4 (39.5–63.8) | 26.1 (22.4–30.8) | 13.8 (11.6–16.1) | <0.0001 |
| Recurrence and/or progression | |||||
| Yes | 287 (63.4) | 57 (42.9) | 155 (68.6) | 75 (79.8) | <0.0001 |
| No | 160 (35.3) | 76 (57.1) | 68 (30.1) | 16 (17.0) | |
| Unknown | 6 (1.3) | 0 (0.0) | 3 (1.3) | 3 (3.2) | |
| Location of first recurrence/progression | |||||
| Distant | 175 (61.0) | 35 (61.4) | 97 (62.6) | 43 (57.3) | 0.0394 |
| Both | 69 (24.0) | 9 (15.8) | 33 (21.3) | 27 (36.0) | |
| Local | 39 (13.6) | 12 (21.1) | 22 (14.2) | 5 (6.7) | |
| Not reported | 4 (1.4) | 1 (1.8) | 3 (1.9) | 0 (0.0) |
*Results reported as number of patients (%) unless otherwise specified.
C/C+E, cisplatin or carboplatin+etoposide; CH, chemotherapy; RT, radiation therapy; SX, surgery.